Ascend Laboratories, LLC recalls

19 federal recalls on file, showing the 6 from the last 12 months. We read every CPSC, FDA, USDA and NHTSA notice for Ascend Laboratories, LLC and put it in plain English.

Recent recalls

  • Ascend amlodipine and olmesartan tablets recalled for dissolution failure

    Ascend Laboratories is recalling one lot of amlodipine and olmesartan medoxomil combination tablets (10mg/40mg) because they do not dissolve properly in the body. This means the medication may not work as intended. The affected lot was distributed nationwide.

    ModerateFDAOct 16, 2026

  • Ascend dabigatran capsules recalled for failed impurity specification

    Ascend Laboratories is recalling one lot of dabigatran etexilate 150 mg capsules. Stability testing at 12 months found out-of-specification results for Impurity II, Impurity III, and total impurities. No injuries have been reported.

    FDAAug 5, 20263 products

  • Ascend dabigatran capsules recalled for failed impurity tests

    Ascend Laboratories is recalling dabigatran etexilate capsules, 110 mg, after an out-of-specification result in 12-month long-term stability testing for Impurity II, Impurity III and total impurities. This means the product failed its impurity specifications. No injuries have been reported.

    FDAJul 29, 20262 products

  • Ascend amlodipine and olmesartan tablets recalled for failed dissolution

    Ascend Laboratories is recalling one lot of amlodipine and olmesartan medoxomil combination tablets (10 mg/20 mg) because the olmesartan medoxomil active ingredient is below the required amount. This means affected tablets may not work as intended to lower blood pressure.

    ModerateFDAJul 29, 2026

  • Ascend minocycline tablets recalled for failed dissolution test

    Ascend Laboratories is recalling Minocycline Hydrochloride Extended-Release Tablets, 115 mg (lot 25141635, expires 4/30/2028) because testing found the tablets did not dissolve properly as required. This affects 360 bottles distributed nationwide. No injuries have been reported.

    ModerateFDAJun 17, 2026

  • Ascend metoprolol succinate tablets recalled for failed dissolution

    Ascend Laboratories is recalling one lot of metoprolol succinate extended-release 25 mg tablets because they failed to meet dissolution specifications. This means the tablets may not break down and release the medication properly in the body. The affected lot was distributed nationwide.

    ModerateFDAMay 20, 2026

Explore other recall topics